Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Amazon Explores AI Content Marketplace With Media Publishers 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
 - EconoTimes)
NEW YORK, April 06, 2018 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (Nasdaq:CGIX) in the United States District Court for the District of New Jersey on behalf of a class consisting of investors who purchased or otherwise acquired Cancer Genetics securities on the open market from March 23, 2017 through April 2, 2018, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
The Complaint alleges the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On April 2, 2018, the Company reported that, following its CEO’s departure, it conducted a comprehensive review of its strategy and organization. This led the Company to record a bad debt expense of $4.4 million and write off $1.8 million of its accounts receivable in the fourth quarter, with a significant portion related to collection issues with accounts receivables recorded after 2015. The Company also reported that, on December 31, 2017, its “cash position and history of losses required management to assess [its] ability to continue operating as a going concern[.]” When the truth was revealed to the investing public, shares of the Company fell $0.55 per share or over 33% to close at $1.10 per share on April 3, 2018, causing shareholders harm.
Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm prior to the June 4, 2018 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
